CN109966349A - A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy - Google Patents
A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy Download PDFInfo
- Publication number
- CN109966349A CN109966349A CN201910407722.1A CN201910407722A CN109966349A CN 109966349 A CN109966349 A CN 109966349A CN 201910407722 A CN201910407722 A CN 201910407722A CN 109966349 A CN109966349 A CN 109966349A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- diabetic retinopathy
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 206010012689 Diabetic retinopathy Diseases 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000008280 blood Substances 0.000 claims abstract description 27
- 210000004369 blood Anatomy 0.000 claims abstract description 27
- 230000002265 prevention Effects 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 14
- 240000001519 Verbena officinalis Species 0.000 claims abstract description 14
- 235000018718 Verbena officinalis Nutrition 0.000 claims abstract description 14
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 12
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims abstract description 12
- 210000000582 semen Anatomy 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000006071 cream Substances 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000002398 materia medica Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- 230000002207 retinal effect Effects 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 230000023597 hemostasis Effects 0.000 abstract description 4
- 230000004089 microcirculation Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000001010 compromised effect Effects 0.000 abstract description 2
- 238000001816 cooling Methods 0.000 abstract description 2
- 230000001771 impaired effect Effects 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000001934 delay Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 20
- 241000700159 Rattus Species 0.000 description 19
- 210000001525 retina Anatomy 0.000 description 11
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 230000004438 eyesight Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 208000009857 Microaneurysm Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 210000000416 exudates and transudate Anatomy 0.000 description 5
- 230000004410 intraocular pressure Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 206010002329 Aneurysm Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000001344 Macular Edema Diseases 0.000 description 3
- 206010025415 Macular oedema Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 201000010230 macular retinal edema Diseases 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 240000005250 Chrysanthemum indicum Species 0.000 description 2
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002143 fluorescein Drugs 0.000 description 2
- 210000004220 fundus oculi Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002647 laser therapy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- 206010018833 Haematocoele Diseases 0.000 description 1
- 208000005873 Hematocele Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 208000036866 Vitreoretinopathy Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 208000024783 anasarca Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940020947 fluorescein sodium Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002189 macula lutea Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The embodiment of the invention discloses a kind of Chinese medicine compositions and preparation method thereof for preventing and treating diabetic retinopathy, belong to technical field of traditional Chinese medicines.The Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-20 parts of Herba Epimedii, 10-20 parts of the horsewhip tip, 10-15 parts of polyporus lucidus, 10-15 parts of wild chrysanthemum, small blood rise 10-15 parts, 10-15 parts of Cortex Eucommiae, 10-15 parts of semen plantaginis.The Chinese medicine composition of the prevention and treatment diabetic retinopathy of the embodiment of the present invention has effects that supplementing qi and nourishing yin, cooling blood and hemostasis, activating microcirculation and removing stasis medicinal; hemorheological property can be improved; it promotes blood circulation; so as to improve the tissue impaired with reparation; compromised retinal is protected, diabetic retinopathy is made to be controlled effectively to a certain extent, delays the development of the state of an illness; and there is preferable safety, it is worth further clinical application research.
Description
Technical field
The present embodiments relate to technical field of traditional Chinese medicines, and in particular to a kind of Chinese medicine group for preventing and treating diabetic retinopathy
Close object and preparation method thereof.
Background technique
Diabetic retinopathy (DR) is that diabetes (diabetes mellitus, DM) most common capilary is concurrent
One of disease, according to statistics, if diabetic's illness 10 years, there may be 50% people to will appear the lesion of retina.Such as fruit disease
Journey is more than 25 years, may have the patient for reaching 90% diabetic retinopathy occur.Diabetic retinopathy is to lead to DM
The main reason for patient's vision declines, if being not treated in time, can cause irreversible visual function damage.
The symptom of patients with diabetic retinopathy:
1, aneurysms: being sign that diabetic retinopathy clinically more early occurs, more exact.Positioned at view
Film inner nuclear layer, roundlet is dotted, often first comes across eyeground Posterior pole, especially in macular area, is distributed in temporo side more.
2, inter-retinal hemorrhage: it is located at capillary vein end, retina deep layer, rounded dotted or flamboyancy.
3, hard exudate: it is located in retina between shape layer and inner nuclear layer.In wax yellow color dot, sheet, boundary is more clear
Chu.More typically in Posterior pole, aneurysms is contained at the center of hard exudate ring, when involving macula area, may occur in which large stretch of asterism spot,
The hard exudate of macula lutea is also the reason of seriously affecting eyesight.
4, macular edema: initial stage oedema further involves inner molecular layer and mind between external plexiform layer and inner nuclear layer
Through fibrous layer, retina holostrome is reached more afterwards.Clinical signs are that retina swelling thickens, and are in opaque appearance, macular edema table
It is now capsule sample, fluorescein angiographic can clearly show that.
After diabetic retinopathy is made a definite diagnosis by fluorescence fundus angiography, controlled according to the state of an illness using drug or laser
It treats.
1, glucose-lowering treatment: use diet control or joint hypoglycemic medicine by glycemic control in normal range (NR) as far as possible, when oral
Medicine cannot be such that hyperglycemia reduces, then need actively to instruct insulin injection according to endocrine doctor.
2, conservative medication: in addition to strict control diabetes, medicine is can be used in early stage (nonproliferative retinopathy type)
Object treatment.
3, the development of retinopathy can laser therapy: be prevented.
4, minimally invasive vitrectomy: minimally invasive vitrectomy is mainly used for the complication of proliferative retinopathy,
Operation purpose be to remove hematocele, cutting machine film, elimination fibr tissue to rely the bracket of growth, the drawing loosened to retina,
Silicone oil or gas are filled in vitreous chamber when necessary, restores normal retina anatomy relationship, the full view of row in operation or after operation
Nethike embrane light is solidifying.
Existing drug or laser therapy can treat diabetic retinopathy to a certain degree, but take medicine for a long time
Object, there are biggish toxic side effects, and there is also certain risks for operation, and are easy recurrent exerbation.
Chinese medicine makes some progress in treatment diabetic retinopathy, and sufficiently shows that the unique of traditional Chinese medicine treats
Effect and advantage.
Summary of the invention
For this purpose, the embodiment of the present invention provide it is a kind of prevent and treat diabetic retinopathy Chinese medicine composition and its preparation side
Method, the Chinese medicine composition is in terms of preventing and treating diabetic retinopathy, with curative for effect, toxic side effect is small, recurrence rate is low
Advantage.
Diabetic retinopathy category Chinese medicine " mesh disease of quenching one's thirst " scope, by traditional Chinese medical discrimination method, diabetes view
Film lesion simple phase and proliferation have no that hemostasis shows based on deficiency of both qi and yin early period, but eyeground and Hemorheology have changed,
When developing to stagnation of QI and blood, on the basis of retinal microcirculation is damaged extensively, retinal neovascularization is generated, is increased with fiber
Raw, retina anasarca and large stretch of bleeding form proliferation period vitreoretinopathy, have prompted to undermine with disease yin and reflect
Conversion, by the development of simple phase to proliferation period, blood stasis syndrome also aggravates therewith, illustrates blood stasis with diabetic retinopathy
Become entire occurrence and development process, the present invention is on the basis of above-mentioned theory, to the Chinese medicine composition of prevention and treatment diabetic retinopathy
Raw material and content have conducted extensive research, finally obtain the content of present invention.
To achieve the goals above, the embodiment of the present invention provides the following technical solutions:
According to a first aspect of the embodiments of the present invention, the embodiment of the invention provides a kind of prevention and treatment diabetic retinopathy
Chinese medicine composition, the Chinese medicine composition is prepared from the following raw materials in parts by weight:
10-20 parts of Herba Epimedii, 10-20 parts of the horsewhip tip, 10-15 parts of polyporus lucidus, 10-15 parts of wild chrysanthemum, small blood rise 10-15
Part, 10-15 parts of Cortex Eucommiae, 10-15 parts of semen plantaginis.
Further, the Chinese medicine composition is prepared from the following raw materials in parts by weight:
18 parts of Herba Epimedii, 16 parts of the horsewhip tip, 13 parts of polyporus lucidus, 13 parts of wild chrysanthemum, small blood rise 12 parts, 12 parts of Cortex Eucommiae, Chinese herbaceous peony
12 parts of son.
According to a second aspect of the embodiments of the present invention, the embodiment of the invention provides a kind of above-mentioned prevention and treatment diabetes views
The preparation method of the Chinese medicine composition of film lesion, the described method comprises the following steps:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 4-6 times is measured water and decocted 1-2 hours, filter
It crosses, for the second time plus 2-4 times is measured water and decocted 0.5-1 hours, and filtration, twice decocting liquid merging staticly settles 18-24 hours, takes supernatant
Liquid, relative density is the clear cream of 1.15-1.25 when being concentrated under reduced pressure into 60 DEG C, is dried to dried cream powder.
According to a third aspect of the embodiments of the present invention, the embodiment of the invention provides a kind of prevention and treatment diabetic retinopathy
Chinese materia medica preparation, Chinese materia medica preparation Chinese medicine composition as made from above-mentioned Chinese medicine composition or above-mentioned method and pharmaceutically
Acceptable auxiliary material is made.
Further, the preparation oral liquor, granule, tablet, any in capsule.
The embodiment of the present invention has the advantages that
The embodiment of the present invention prevention and treatment diabetic retinopathy Chinese medicine composition with Herba Epimedii, the horsewhip tip, polyporus lucidus,
Wild chrysanthemum, small blood rises, Cortex Eucommiae, semen plantaginis are raw material, wherein Herba Epimedii QI invigorating is reinforced the kidney, in the hope of it；The dispelling wind and eliminating dampness of the horsewhip tip,
Promoting blood circulation to remove blood stasis；Polyporus lucidus replenishing qi and blood, tranquilizing mind, strengthening the spleen and stomach；Wild chrysanthemum clearing heat and removing internal heat, clears liver and improve vision at antibacterial anti-inflammatory；Small blood, which is risen, dispels
Wind promoting blood circulation, removing toxicity for detumescence, hemostasis；Cortex Eucommiae tonifies the liver and kidney, strengthens muscles and bones；Tonify the liver and kidney, strengthen muscles and bones reducing fever and causing diuresis, excreting dampness is logical
Leaching.The above raw material compounding, has effects that supplementing qi and nourishing yin, cooling blood and hemostasis, activating microcirculation and removing stasis medicinal, can improve hemorheological property, promote
Blood circulation protects compromised retinal to repair impaired tissue, obtains diabetic retinopathy to a certain extent
To effective control, delay the development of the state of an illness.
The clinical effectiveness of the Chinese medicine composition of the prevention and treatment diabetic retinopathy of the embodiment of the present invention is better than simple oxybenzene
Sulfonic acid calcium capsule can be obviously improved patient's vision, promote fundus hemorrhage exudation to absorb, reduce eyeground microaneurysm, mitigate eye
Bottom lesion to be conducive to prevent and reduce the blinding of patient, disable, and has preferable safety, is worth further clinical
Application study.
Specific embodiment
Embodiments of the present invention are illustrated by particular specific embodiment below, those skilled in the art can be by this explanation
Content disclosed by book is understood other advantages and efficacy of the present invention easily, it is clear that described embodiment is the present invention one
Section Example, instead of all the embodiments.Based on the embodiments of the present invention, those of ordinary skill in the art are not doing
Every other embodiment obtained under the premise of creative work out, shall fall within the protection scope of the present invention.
Embodiment 1
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of the present embodiment include: 16 grams of Herba Epimedii, 14 grams of the horsewhip tip,
10 grams of polyporus lucidus, 13 grams of wild chrysanthemum, small blood rise 10 grams, 13 grams of Cortex Eucommiae, 12 grams of semen plantaginis.
The preparation method of the Chinese medicine composition of the present embodiment the following steps are included:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 4 times of amount water decoct 2 hours, filtration, the
Secondary plus 2 times of amount water decoct 1 hour, and filtration, twice decocting liquid merging staticly settles 18 hours, take supernatant, are concentrated under reduced pressure into 60
DEG C when relative density be 1.22 clear cream, be dried to dried cream powder.
Embodiment 2
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of the present embodiment include: 18 grams of Herba Epimedii, 16 grams of the horsewhip tip,
13 grams of polyporus lucidus, 13 grams of wild chrysanthemum, small blood rise 12 grams, 12 grams of Cortex Eucommiae, 12 grams of semen plantaginis.
The preparation method of the Chinese medicine composition of the present embodiment the following steps are included:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 4.5 times of amount water decoct 1.5 hours, filter
It crosses, for the second time plus 3 times of amount water decoct 1 hour, and filtration, twice decocting liquid merging staticly settles 18 hours, takes supernatant, reduced pressure
The clear cream that relative density is 1.18 when to 60 DEG C, is dried to dried cream powder.
Embodiment 3
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of the present embodiment include: 20 grams of Herba Epimedii, 18 grams of the horsewhip tip,
12 grams of polyporus lucidus, 12 grams of wild chrysanthemum, small blood rise 12 grams, 11 grams of Cortex Eucommiae, 10 grams of semen plantaginis.
The preparation method of the Chinese medicine composition of the present embodiment the following steps are included:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 5 times of amount water decoct 2 hours, filtration, the
Secondary plus 3 times of amount water decoct 0.5 hour, and filtration, twice decocting liquid merging staticly settles 24 hours, take supernatant, are concentrated under reduced pressure into
The clear cream that relative density is 1.25 at 60 DEG C, is dried to dried cream powder.
Embodiment 4
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of the present embodiment include: 15 grams of Herba Epimedii, 18 grams of the horsewhip tip,
12 grams of polyporus lucidus, 12 grams of wild chrysanthemum, small blood rise 12 grams, 10 grams of Cortex Eucommiae, 12 grams of semen plantaginis.
The preparation method of the Chinese medicine composition of the present embodiment the following steps are included:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 6 times of amount water decoct 1 hour, filtration, the
Secondary plus 2 times of amount water decoct 1 hour, and filtration, twice decocting liquid merging staticly settles 24 hours, take supernatant, are concentrated under reduced pressure into 60
DEG C when relative density be 1.18 clear cream, be dried to dried cream powder.
Embodiment 5
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of the present embodiment include: 18 grams of Herba Epimedii, 20 grams of the horsewhip tip,
15 grams of polyporus lucidus, 14 grams of wild chrysanthemum, small blood rise 10 grams, 15 grams of Cortex Eucommiae, 14 grams of semen plantaginis.
The preparation method of the Chinese medicine composition of the present embodiment the following steps are included:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 5 times of amount water decoct 1.5 hours, filtration,
For the second time plus 3 times of amount water decoct 1 hour, and filtration, twice decocting liquid merging staticly settles 20 hours, takes supernatant, is concentrated under reduced pressure into
The clear cream that relative density is 1.15 at 60 DEG C, is dried to dried cream powder.
Embodiment 6
The oral solutions of the prevention and treatment diabetic retinopathy of the present embodiment, dried cream powder made from embodiment 1-5 is distinguished
It is dissolved with water, sucrose and potassium sorbate, encapsulating is then added, oral solutions are made in sterilizing.
Embodiment 7
The present embodiment prevention and treatment diabetic retinopathy granule, by dried cream powder made from embodiment 1-5 respectively with
Mannitol carries out ingredient, and granule is made according to the method for conventional Chinese materia medica preparation.
Embodiment 8
The tablet of the prevention and treatment diabetic retinopathy of the present embodiment, respectively and firmly by dried cream powder made from embodiment 1-5
Fatty acid magnesium carries out ingredient, and tablet is made according to the method for conventional Chinese materia medica preparation.
Embodiment 9
The capsule of the prevention and treatment diabetic retinopathy of the present embodiment, by dried cream powder made from embodiment 1-5, according to normal
Capsule is made in the method for rule Chinese materia medica preparation.
Comparative example 1
This comparative example prevention and treatment diabetic retinopathy Chinese medicine composition the difference from embodiment 1 is that, this implementation
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of example includes: 16 grams of Radix Astragali, 14 grams of the horsewhip tip, 10 grams of polyporus lucidus, mother chrysanthemum
Spend 13 grams, small blood rise 10 grams, 13 grams of Cortex Eucommiae, 12 grams of semen plantaginis.
Comparative example 2
This comparative example prevention and treatment diabetic retinopathy Chinese medicine composition the difference from embodiment 1 is that, this implementation
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of example includes: 8 grams of Herba Epimedii, 14 grams of the horsewhip tip, 18 grams of polyporus lucidus, mother chrysanthemum
Spend 13 grams, small blood rise 10 grams, 13 grams of Cortex Eucommiae, 12 grams of semen plantaginis.
Test case
One, in order to illustrate the Chinese medicine composition of the embodiment of the present invention to the preventive and therapeutic effect of diabetic retinopathy, this hair
It is bright to have carried out following zoopery.
Experimental animal: SD rat (SPF grades, male), weight 180-220g.Standard feed is fed, feeding environment: temperature
18-20 DEG C, humidity 50-55%, lighting hours 12h, day alternates with night.
Experimental group: SD rat is randomly divided into Normal group (5) and modeling group (80).Modeling group Rat Fast
12 hours, through abdominal cavity one injection streptozotocin 50mg/kg, rear molding venous blood sampling surveyed non-fasting blood-glucose within 3 days, and fasting blood-glucose is dense
When degree is greater than 16.7mmol/L (Johnson & Johnson's blood glucose meter is surveyed), i.e. modeling success, Normal group injects isometric physiological saline
As control.Blood glucose is still not less than this 68 horizontal diabetes rat and is divided into test group 1-5 according to blood glucose level pairing after 1 week
(every group of 9 rats), control group 1-2 (every group of 9 rats) and model control group (5).
Start to be administered, medication are as follows:
Test group 1-5: carrying out stomach-filling using Chinese medicine composition made from 1-5 of the embodiment of the present invention respectively, and dosage is
1.5g·kg-1·d-1.Control group 1-2: stomach-filling, dosage are carried out using Chinese medicine composition made from comparative example 1-2 of the present invention respectively
For 1.5gkg-1·d-1.Normal group and model control group: with physiological saline 10ml/kg stomach-filling.The above each group rat connects
Continuous administration 8 weeks.
Tonometry: 4 weeks and 8 weeks after modeling success, according to rat body weight intraperitoneal injection anesthetic yellow Jackets
(50mg/kg) measures the intraocular pressure of each rat after rat anesthesia using Tonolab tonometer.Test result is shown in Table 1.
Table 1
| Group | 4 weeks/mmHg | 8 weeks/mmHg |
| Blank control group | 8.6±0.7 | 8.7±0.7 |
| Test group 1 | 9.8±0.6 | 11.0±0.5 |
| Test group 2 | 9.7±0.6 | 10.8±0.6 |
| Test group 3 | 10.2±0.8 | 11.4±0.4 |
| Test group 4 | 10.0±0.7 | 11.2±0.5 |
| Test group 5 | 10.3±0.7 | 11.5±0.5 |
| Control group 1 | 10.9±0.6 | 16.6±0.4 |
| Control group 2 | 11.0±0.7 | 15.8±0.6 |
| Model control group | 11.7±0.5 | 18.2±0.4 |
The result shows that: relative to blank control group, over time, test group, control group, model control group rat
Intraocular pressure exists to be increased in various degree.Rats in test groups is below control group, and rats in test groups in treatment 4 weeks, 8 weeks intraocular pressures
Intraocular pressure amplification is significantly lower than control group, through examining two groups of comparing differences statistically significant (P < 0.05), illustrates implementation of the present invention
The Chinese medicine composition of example, which increases intraocular pressure caused by diabetic retinopathy, has significant therapeutic effect.
Fluorescein fundus angiography (FFA) checks: checking in the 4th and 8 week row rat eyes FFA.Rat anesthesia is adopted
With Tropicamide and Phenylephrine ocular fluid mydriasis, after 10% fluorescein sodium (2mg/kg) is injected intraperitoneally, confocal laser fundus fluorescence is being synchronized
Fundus tissue structure is detected under angiographic instrument.
FFA the result shows that, blank control group does not observe aneurysms, hard exudate, blood spots, velveteen spot and Macular
The pathological changes such as oedema.There is different degrees of microaneurysm, petechial hemorrhage in test group, control group, model control group, through than
Compared with rats in test groups microaneurysm quantity, fundus hemorrhage degree are lighter than control group.Each group rat retinal microvascular tumor quantity
Comparison result is shown in Table 2.
Table 2
The result shows that: relative to blank control group, over time, test group, control group, model control group rat
Retina microangioma quantity exists to be increased in various degree.Rats in test groups is in treatment 4 weeks, 8 weeks retina microangiomas
Quantity is less than control group, and has lower microaneurysm quantity increment rate, through examining two groups of comparing differences to have statistics meaning
Adopted (P < 0.05), it is micro- caused by diabetic retinopathy to illustrate that the Chinese medicine composition of the embodiment of the present invention can be treated effectively
Hemangioma.
Two, in order to verify therapeutic effect of the Chinese medicine composition to diabetic retinopathy of the embodiment of the present invention, this hair
It is bright to have carried out following clinical test.
1 general information
68 diagnosis of diabetic retinopathy patients for selecting this test of voluntary participation are included in standard: referring to " Chinese medicine
Clinical Researches of New Drugs guideline " diagnosis of diabetic retinopathy standard in (tentative).There is diabetic symptom, and in 1d
Plasma glucose concentration >=11.1mmol/L when any, or on an empty stomach after at least 8h, plasma glucose concentration >=7.0mmol/
Plasma glucose concentration >=11.1mmol/L of L or standard 75g dextrose tolerance test (OGTT) 2h.Diabetic retinopathy
Become staging scale: there were microaneurysm, small bleeding in I phase；II phase, there is hard exudate；There is the soft exudation of flocculence in III phase.Row
Except with the severe primaries such as angiocarpy, liver, kidney, hemopoietic system disease and mental patient, gestation, breast feeding women and have
Allergies person.All patients refuse to obey the drug that may influence to observe result with other during treatment.
Patient is randomly divided into 2 groups.Treatment group 34, wherein male 20, female 14；Age 20-68 years old, average (42.5
± 6.2) year；Course of disease 0.5-8, average (5.2 ± 1.8) year.Control group 34, male 18, female 16；It age 20-65 years old, puts down
(40.6 ± 5.5) year；Course of disease 0.5-9, average (6.0 ± 1.6) year.2 groups of patient's general information comparing differences are without statistics
Meaning (P > 0.05), is comparable.
2 treatment methods
Treatment group: the Chinese medicine composition of the embodiment of the present invention 2.1 dose is divided to two days and takes, and is taken for every natural gift early, middle and late 3 times.
Control group: calcium hydrophenyl sulfonate capsule takes orally, 0.5g/ times, 3 times/day.
3 criterions of therapeutical effect
It is effective: eyesight progress >=4 rows or eyesight progress >=1.0；Fundus oculi changes show retinal angiomatous number by (+++)
It reduces to (++), or is reduced by (++) to (+), or by (+) to disappearance；Fundus hemorrhage amount is reduced by (+++) to (+), or by (+
+) extremely disappear；Seepage discharge is reduced by (+++) to (++), or is reduced by (++) to (+), or by (+) to disappearance；Microaneurysm number,
Amount of bleeding, seepage discharge change have 2 and 2 or more indexs to reach requirement.
It is effective: eyesight progress >=2 rows；Fundus oculi changes show that retinal angiomatous number is reduced by (+++) to (++), or by (+
+) reduce to (+), or by (+) to disappearance；Fundus hemorrhage amount is reduced by (+++) to (+), or by (++) to disappearance；Seepage discharge by
(+++) is reduced to (++), or is reduced by (++) to (+), or by (+) to disappearance；Microaneurysm number, amount of bleeding, seepage discharge change
There is 1 index to reach requirement.
Invalid: indices are not up to the above standard.
Deteriorate: 2 row of eyesight room for manoeuvre >；Fluorescence fundus angiography inspection shows that retina blood capillary expands without perfusion area
Greatly, macular edema aggravates, and vascular leakage increases.
4 results
2 groups continuously treatment counted curative effect after 3 months, the results are shown in Table 3.
Table 3
| Group | Number of cases | It is effective | Effectively | In vain | Deteriorate | Total effective rate |
| Treatment group | 34 | 20 | 11 | 2 | 1 | 91.18 |
| Control group | 34 | 10 | 12 | 4 | 8 | 64.71 |
The result shows that: treatment group's patient's total effective rate is 91.18%, and control group patient's total effective rate is 64.71%, through examining
It is statistically significant (P < 0.05) to test two groups of comparing differences, illustrates the Chinese medicine composition of the embodiment of the present invention to diabetes view
The therapeutic effect of film lesion is better than existing drug calcium hydrophenyl sulfonate capsule.
To treatment group, blood urine routine, liver function index of correlation and renal function index of correlation are supervised during treatment simultaneously
It surveys, it is no abnormal.Further, effective to treatment group and effective patient do not recur up to follow-up in 2 years
Situation.
Although above having used general explanation and specific embodiment, the present invention is described in detail, at this
On the basis of invention, it can be made some modifications or improvements, this will be apparent to those skilled in the art.Therefore,
These modifications or improvements without departing from theon the basis of the spirit of the present invention are fallen within the scope of the claimed invention.
Claims (5)
1. a kind of Chinese medicine composition for preventing and treating diabetic retinopathy, which is characterized in that the Chinese medicine composition is by following heavy
The raw material of amount number is made:
10-20 parts of Herba Epimedii, 10-20 parts of the horsewhip tip, 10-15 parts of polyporus lucidus, 10-15 parts of wild chrysanthemum, small blood rise 10-15 parts, Du
It is 10-15 parts secondary, 10-15 parts of semen plantaginis.
2. the Chinese medicine composition of prevention and treatment diabetic retinopathy according to claim 1, which is characterized in that the Chinese medicine
Composition is prepared from the following raw materials in parts by weight:
18 parts of Herba Epimedii, 16 parts of the horsewhip tip, 13 parts of polyporus lucidus, 13 parts of wild chrysanthemum, small blood rise 12 parts, 12 parts of Cortex Eucommiae, semen plantaginis 12
Part.
3. a kind of preparation method of the Chinese medicine composition of prevention and treatment diabetic retinopathy of any of claims 1 or 2, feature
It is, the described method comprises the following steps:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 4-6 times is measured water and decocted 1-2 hours, filtration, the
Secondary to add 2-4 times to measure water decoction 0.5-1 hours, filtration, decocting liquid merging twice staticly settles 18-24 hours, takes supernatant, depressurizes
Relative density is the clear cream of 1.15-1.25 when being concentrated into 60 DEG C, is dried to dried cream powder.
4. a kind of Chinese materia medica preparation for preventing and treating diabetic retinopathy, which is characterized in that the Chinese materia medica preparation by claim 1 or
Chinese medicine composition made from Chinese medicine composition described in 2 or method as claimed in claim 3 and pharmaceutically acceptable auxiliary material system
At.
5. the Chinese materia medica preparation of prevention and treatment diabetic retinopathy according to claim 4, which is characterized in that the preparation mouth
Take liquor, granule, tablet, any in capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910407722.1A CN109966349A (en) | 2019-05-16 | 2019-05-16 | A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910407722.1A CN109966349A (en) | 2019-05-16 | 2019-05-16 | A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109966349A true CN109966349A (en) | 2019-07-05 |
Family
ID=67073713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910407722.1A Pending CN109966349A (en) | 2019-05-16 | 2019-05-16 | A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109966349A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247542A (en) * | 2010-12-23 | 2011-11-23 | 陈玉堂 | Medicine for treating diabetes and kidney disease, cataract and other diabetic complications |
| CN103120767A (en) * | 2013-03-21 | 2013-05-29 | 王钢柱 | Traditional Chinese medicine for treating diabetic retinopathy and preparation method thereof |
| CN104306579A (en) * | 2014-11-03 | 2015-01-28 | 南京市中医药 | Traditional Chinese medicine for treating diabetic retinopathy of yin deficiency and blood stagnation as well as preparation method and application thereof |
| CN104435487A (en) * | 2014-12-06 | 2015-03-25 | 周连才 | Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof |
-
2019
- 2019-05-16 CN CN201910407722.1A patent/CN109966349A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247542A (en) * | 2010-12-23 | 2011-11-23 | 陈玉堂 | Medicine for treating diabetes and kidney disease, cataract and other diabetic complications |
| CN103120767A (en) * | 2013-03-21 | 2013-05-29 | 王钢柱 | Traditional Chinese medicine for treating diabetic retinopathy and preparation method thereof |
| CN104306579A (en) * | 2014-11-03 | 2015-01-28 | 南京市中医药 | Traditional Chinese medicine for treating diabetic retinopathy of yin deficiency and blood stagnation as well as preparation method and application thereof |
| CN104435487A (en) * | 2014-12-06 | 2015-03-25 | 周连才 | Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 高天舒 等: "《实用中医内分泌病学》", 28 February 2018, 辽宁科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kapp et al. | Limitations of high dose intra-arterial 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy for malignant gliomas | |
| CN103845418B (en) | A kind of Chinese medicine composition for the treatment of retinal hemorrhage and uses thereof | |
| CN102813666B (en) | The application of arasaponin R1 in the medicine of control neuro-ophthalmic disease | |
| WO2012079419A1 (en) | Pharmaceutical composition for treating macular degeneration | |
| CN103565801B (en) | For treating compositions and the said composition application in treatment ocular disease of eyeground macular edema | |
| CN109966349A (en) | A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy | |
| CN104435487A (en) | Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof | |
| CN114588236B (en) | Use of a composition in the preparation of a medicament | |
| CN104306546B (en) | A kind of Chinese medicine composition and its decoction, pill and powder for being used to treat optic atrophy | |
| CN104840941B (en) | The application of vascular study polypeptide with integrin compatibility and binding ability and matrix metalloproteinase rejection ability | |
| CN108338980A (en) | Purposes of the chlorogenic acid in the drug for preparing prevention inflammation of eye section | |
| CN112336833A (en) | A Chinese medicinal composition for treating hemorrhagic eye diseases, and its preparation method | |
| CN106389948A (en) | Traditional Chinese medicine composition for effectively alleviating lumbar pain caused by kidney deficiency | |
| CN104491612A (en) | Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy | |
| CN108210683A (en) | Pharmaceutical composition for treating glaucoma | |
| CN101390973A (en) | Use of traditional Chinese medicine in preparing medicine for treating retinal vein obstruction | |
| CN104324139B (en) | A kind of pharmaceutical composition treating xerophthalmia | |
| CN103393757B (en) | Traditional Chinese medicine decoction for treating radioactive brain damage | |
| CN1132610C (en) | Chinese medicine for treating diabetes and neurovascular lesion of both feet and its preparing process | |
| CN103877430B (en) | A kind of medicine and preparation method for the treatment of degeneration of macula | |
| CN100500192C (en) | Medicine for treating eye vitreous hemorrhage and turbidity and its preparation method | |
| CN110934980B (en) | Traditional Chinese medicine formula and application thereof | |
| US20240285573A1 (en) | Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor | |
| CN107714709A (en) | Otoginsenoside and its salt are preparing the purposes in treating cataract medicine | |
| CN106668240A (en) | Pharmaceutical composition for treating vitreous opacity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190705 |
|
| RJ01 | Rejection of invention patent application after publication |